STOCKS TELEGRAPH

Tag: TBPH Stock

  • Theravance Biopharma, Inc. (TBPH) Stock Consistently Declining, Here’s Why

    Theravance Biopharma, Inc. (TBPH) Stock Consistently Declining, Here’s Why

    Theravance Biopharma, Inc. (TBPH), a diversified biopharmaceutical company, has declined 5.24% in aftermarket trading session. Consequently, TBPH stock is trading at $7.59 at the time of the writing. On Friday, TBPH closed the day $8.01 after declining 5.21% during regular trading hours. The uncertainty regarding clinical trials being performed by the company has made the stock decline continuously during the last few months.

    TBPH Q3 2021 Operational Results

    On 3rd November, TBPH reported the operational results for the third quarter of the fiscal year 2021. The quarter ended on 30th September 2021. The company generated total revenue of $13.19 million against $18.25 million for the same period of 2020. The total costs and expenses bore by the company during the three months was $66.80 million against $94.87 million for the same period of 2020. The net loss suffered by the company during the three months stood at $35.30 million ($0.48 per basic and diluted share) against $73.64 million ($1.16 per basic and diluted share) for the same period of 2020

    Financial Guidance for Upcoming Period

    TBPH also updated the financial guidance for the complete year 2021. The company expected that the Research and Development expenses for the full year 2021 would stand at $180 million to $190 million. Alongside, there was an expectation that the Selling, General, and Administrative expenses for the full year 2021 would stand in the range of $70 million to $80 million.

    Executive Commentary

    Rick E Winningham, Chief Executive Officer of TBPH, while commenting on the results said that the quarter under discussion was about executing its strategies to create and implement a new business model. He said that the company is executing against the strategic plan it announced during the mid of September. He said that the focus of the company is on driving the growth of YUPELRI, streamlining R&D investment, and optimizing its asset portfolio to maximize shareholder value.

    Future Outlook for TBPH

    During the last 6 months, TBPH has declined more than 50%. The prime reason for that could be the negative sentiments associated with stock throughout the period due to the effects the pandemic imparted throughout the period. However, the analysts are hopeful that going forward, the stock is in a good shape to pay back the shareholders with benefits.

  • Theravance (TBPH) Stock Fell 9% Last Session, Why?

    In after-hours trading, Theravance Biopharma Inc. (TBPH) was trading at $15.50, down -9.36%. In regular session, Theravance stock closed at $17.10, up by 2.70%. TBPH stock volume on Thursday was 0.45 million shares, which was above the average daily volume of 0.29 million shares over the past 50 days. Over the past 12 months, TBPH shares have lost -22.48%, and they have lost -3.01% over the last week.

    The TBPH stock has lost -14.54% over the past three months, and -10.28% over the past six months. Also, TBPH currently has a market capitalization of $1.12 billion and 64.49 million outstanding shares. An announcement about the pricing of its underwritten public offering triggered a rapid decline in TBPH stock.

    What price has TBPH set for its offering?

    Theravance is a biopharmaceutical company focused on discovering, developing and commercializing drugs that specifically target the organs of interest. To meet the needs of patients better, TBPH is dedicated to developing new small-molecule drugs. TBPH focuses its research efforts on immunology and inflammation.

    TBPH combines insights and innovation at each stage of its business and uses its internal capabilities, as well as those of its global partners, to achieve its purpose. TBPH employs its expertise in organ-selective pathology to develop new drugs that aim to increase a patient’s therapeutic index and minimize systemic side effects while maximizing efficacy.

    A public offering of 6,700,000 ordinary shares of Theravance was priced at $15 per share in an underwritten public offering announced by the company.

    • Pre-discounting, underwriting expenses and commissions, TBPH is expected to receive gross proceeds of $100.5 million.
    • TBPH has also given the underwriters the option to purchase up to an additional 1,005,000 ordinary shares during the 30-day period following the public offering.
    • Under normal circumstances, TBPH expects its offering to close on June 29, 2021.
    • Joint bookrunners SVB Leerink and Evercore ISI handled TBPH’s offering.
    • TBPH also engaged Credit Suisse as a bookrunner.
    • C. Wainwright & Co. served as TBPH’s lead manager for that offering.

    TBPH’s recent study results:

    Theravance (TBPH) also this week released top-line data in a Phase 2 study using nezulcitinib at 3 mg once-daily compared to a placebo.

    • TBPH is developing nezulcitinib, an investigational, inhaled pan-Janus kinase (JAK) inhibitor for the treatment of hospitalized patients who have acute lung injury and impaired oxygenation associated with COVID-19.
    • In TBPH’s study, patients hospitalized with COVID-19 with impaired oxygenation were randomized, compared to a control group, and treated with a placebo.
    • TBPH evaluated key endpoints through Day 28.
    • About 99% of the participants received steroids as part of the study’s standard of care.
    • Theravance (TBPH) will share these results with FDA, regulatory agencies, and other institutions to gain feedback on protocols for further studies of nezulcitinib in acute pulmonary inflammation.